Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2
Indole-3-PROpionic Acid Clinical Trials - a Pilot Study Part 2 (iPROACT-pilot2)
Glostrup University Hospital, Copenhagen
32 participants
Aug 4, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this trial is to investigate the biological effects of oral supplementation with indole-3-propionic acid (IPA) taken twice daily in healthy adults. The main scientific questions are: * Does supplementation with IPA increase the abundance of regulatory T cells in the blood? Regulatory T cells are believed to play an important role in preventing autoimmune diseases. * Does supplementation with IPA increase the concentration of brain-derived neurotrophic factor (BDNF) in the blood? BDNF is believed to play an important role in maintaining brain health. * Does supplementation with IPA affect blood analyses commonly performed to assess the risk of metabolic disorders like type 2 diabetes and cardiovascular diseases? Participants will: * Take capsules to achieve a total daily dose of 1000 mg of IPA or placebo: 500 mg every morning and 500 mg every evening for 14 days. * Visit the clinic at the beginning (day 1) and at the end (day 15) of the supplementation period to deliver blood, urine and fecal samples, have simple measurements performed, fulfil questionnaires and report any side effects.
Eligibility
Inclusion Criteria2
- Healthy women and men ≥18 and ≤65 years of age
- Deemed mentally and physically able to participate
Exclusion Criteria4
- Diagnosis of gut-, heart-, liver-, kidney or immune-related disorders
- Use of antibiotics within the last month
- Pregnancy, lactation or childbirth within the last five months
- Use of prescription medication
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Active capsules are taken orally and contain 250 mg of IPA each.
Two capsules are taken every morning and two capsules are taken every evening for 14 consecutive days. Placebo capsules are taken orally and contain maltodextrin.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07105514